Samsung Bioepis Moves Forward With Soliris Rival
Completes Phase III Trial For SB12 Proposed Eculizumab Biosimilar
Samsung Bioepis has confirmed completion of its Phase III trial for a proposed biosimilar to Soliris, putting it ahead of rival developer Amgen which has negotiated a date-certain US launch.
